New drug design is a long (5 years), costly (50-100M$) and unproductive process (1% success rate from hit to pre-clinical candidate)… Iktos aims to leverage big data and AI to bring radical improvement to this process.
Artificial intelligence for new drug design
Iktos has invented and is developing a truly innovative and disruptive artificial intelligence technology for ligand-based de novo drug design, focusing on multi parametric optimization (MPO).
Deep learning generative algorithms
Our proprietary technology is built upon the latest developments in deep learning algorithms. In a few hours, our technology can design new, druggable and synthesizable molecules, that are optimized to match all your selection criteria.
A virtual designing technology
Virtual screening has many well-known limitations that limit its usefulness in practice: time consuming, strong expertise, dependence upon fragments libraries, constrained by a priori scaffold definitions, limitation to a small number of targets...
In contrast, Iktos technology is a “virtual designing” algorithm that is able to create novel molecular structures which are optimized to match a given multi-objective blueprint.
Iktos is a virtual designing technology vs Virtual screening.
Iktos has no a priori on the scaffold, it identifies what is important for the activity vs Need to define a fixed scaffold and allowed structural modifications to the chosen places.
Iktos does not depend on databases of molecular fragments, its diversity is almost infinite vs Conventional combinatorial approaches, that are dependent upon availability of fragment databases
The number of parameters to optimize does not modify the performance of Iktos vs With traditional approaches, the size of the database must increase exponentially with the number of constraints
In average, Iktos identifies promising molecules for your project in 48 hours vs Need a high amount of data preparation, computation time and expertise
In a matter of days, Iktos provides you with optimal virtual compounds that match your expectations. With Iktos, inverse-QSAR becomes a child’s play.
You have a collection of diverse molecules measured on one or several objectives. Iktos is able to virtually design a series of new structures based on new scaffolds, for any given blueprint.
After several months of effort, you are struggling to find a molecule which makes the consensus. Iktos will help you to design new structures, close to your chemical series, that optimize your targets.
You have a promising lead but you miss one or two objectives. Iktos will help you to design a molecule very similar to your best lead, with optimal characteristics fulfilling your remaining objectives.
Pharma R&D executive
Experienced pharma R&D executive consultant in data science and strategy for pharma/healthcare.
PhD in artificial intelligence, expert in Deep Learning and Big data infrastructure
PhD in organometallic chemistry, expert in chemoinformatics.
THEY TRUST US
Iktos initiates a research collaboration with Laboratoires Servier
Iktos initiates a research collaboration with Laboratoires Pierre Fabre
Iktos successfully closes its initial fundraising round for 680k€ with private investors and business angels.
Iktos wins the Innov'Up Proto challenge sponsored by the Paris region and will get a 100k€ to help develop our SaaS AI-powered de novo drug design software
Iktos is selected by Paris region start-up incubator Scientipole Initiative.
Iktos application to Concours Mondial de l'Innovation (CMI) phase 2 is selected for oral presentation
Iktos application to Concours de l'Innovation Numérique (CIN) is selected for oral presentation
Iktos is labelled by Cap Digital for its application to CMI and CIN challenges.
61 RUE BLOMET 75015 PARIS, FRANCE Email: email@example.com